The Limited Times

Now you can see non-English news...

Sanofi, GSK, Gilead, MSD ...: these giants who missed the boat of vaccination

2021-12-21T18:24:29.854Z

DECRYPTION - Only certain laboratories have succeeded. If the health crisis has propelled Pfizer, BioNTech and Moderna to the forefront, the race for vaccines and treatments has been an obstacle course for several heavyweights in the pharmaceutical industry. Sanofi, world number four in vaccines, is one of them. The first French laboratory will not have succeeded in releasing its anti-Covid serum this year, showing several delays. A blow in terms of



If the health crisis has propelled Pfizer, BioNTech and Moderna to the forefront, the race for vaccines and treatments has been an obstacle course for several heavyweights in the pharmaceutical industry.

Sanofi, world number four in vaccines, is one of them.

The first French laboratory will not have succeeded in releasing its anti-Covid serum this year, showing several delays.

A blow in terms of image, public opinion not having digested that France does not have "its" vaccine.

Sanofi is still betting on positioning as a reminder but should only get a small piece of the pie.

Disappointment for AstraZeneca

If its British ally GSK - which is developing the adjuvant - has just obtained the green light from Brussels for Xevudy, an early treatment of Covid, it has not performed well either. The world number two in vaccines has had to put an end to its collaboration with the Chinese Clover Biopharmaceuticals.

He still has a second generation vaccine project with German biotech ...

This article is for subscribers only.

You have 68% left to discover.

To cultivate one's freedom is to cultivate one's curiosity.

Continue reading your article for € 1 the first month

I ENJOY IT

Already subscribed?

Log in

Source: lefigaro

All business articles on 2021-12-21

You may like

Tech/Game 2022-02-23T16:16:59.796Z

Trends 24h

Business 2022-05-25T09:41:26.703Z

Latest

© Communities 2019 - Privacy